Newer drugs in obesity management

Definition

Target Population: Pediatric obesity is defined as a Body Mass Index (BMI) ≥ 95th percentile for age and sex, or a BMI ≥ 30 kg/m² (whichever is lower). Pharmacotherapy is indicated as an adjunct to intensive Health Behavior and Lifestyle Treatment (HBLT) in adolescents aged ≥ 12 years with a BMI ≥ 95th percentile and weight-related comorbidities, or severe obesity (BMI ≥ 120% of the 95th percentile).
Shift in Management: Paradigm change from traditional low-efficacy oral medications (e.g., orlistat) to high-efficacy, neuro-hormonal targeted therapies like Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs).

Age ≥ 12 Years: Considered for patients with obesity (BMI ≥ 95th percentile) to reduce BMI and improve metabolic complications.
Severe Obesity: Highly recommended for adolescents with a BMI ≥ 120% of the 95th percentile.
Genetic/Syndromic Obesity: Indicated from age ≥ 6 years for specific monogenic mutations.

Mechanism of Action: Long-acting GLP-1 receptor agonist; increases glucose-dependent insulin secretion, delays gastric emptying, and centrally signals satiety in the hypothalamus.
Approval & Age: Approved for adolescents aged ≥ 12 years for chronic weight management.
Dosing Regimen: Administered once weekly via subcutaneous injection.
- Titration: Initiated at 0.25 mg weekly for 4 weeks; up-titrated monthly (0.5 mg, 1.0 mg, 1.7 mg) to a maintenance dose of 2.4 mg weekly as tolerated.
Clinical Efficacy: STEP TEENS Trial demonstrated a mean reduction in BMI of 16.1% at week 68 compared to placebo.

Mechanism of Action: Daily GLP-1 receptor agonist.
Approval & Age: Approved for adolescents aged ≥ 12 years.
Dosing Regimen: Once-daily subcutaneous injection.
- Titration: Started at 0.6 mg daily; increased by 0.6 mg increments weekly to a maximum maintenance dose of 3.0 mg daily.
Clinical Efficacy: Produces a modest ~4.5% to 5% reduction in BMI z-score at 56 weeks.

Mechanism of Action: Dual Glucose-Dependent Insulinotropic Polypeptide (GIP) and GLP-1 receptor agonist; synergizes weight loss via enhanced central anorexigenic signaling.
Status (2026): Extrapolated from adult success and validated via pediatric trials (e.g., SURPASS-PEDS), approved for adolescents aged ≥ 10 years with Type 2 Diabetes, showing significant weight/BMI reductions (mean drop up to 8.8 kg/m²), and actively integrated off-label or under expanded indications for adolescent severe obesity.
Dosing: Once-weekly subcutaneous injection, starting at 2.5 mg and titrating up to a maximum of 10 mg or 15 mg weekly.

Mechanism of Action: Combination therapy. Phentermine acts as a sympathomimetic anorectic (increases norepinephrine release in the central nervous system); Topiramate modulates GABA receptors and inhibits AMPA/kainate receptors to enhance satiety.
Approval & Age: Approved for adolescents aged ≥ 12 years.
Dosing Regimen: Once-daily oral capsule taken in the morning (to prevent insomnia). Initiated at 3.75 mg/23 mg for 14 days, advanced to a recommended dose of 7.5 mg/46 mg. Maximum dose is 15 mg/92 mg daily.
Clinical Efficacy: The EQUIP2 trial showed a mean BMI reduction of ~10.4% at 56 weeks.

Mechanism of Action: Melanocortin-4 Receptor (MC4R) agonist. Bypasses upstream genetic defects in the leptin-melanocortin pathway to restore downstream satiety signaling.
Approval & Age: Approved for pediatric patients aged ≥ 6 years.
Specific Indications: Genetically confirmed obesity due to:
1. Pro-opiomelanocortin (POMC) deficiency
2. Proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency
3. Leptin receptor (LEPR) deficiency
4. Bardet-Biedl Syndrome (BBS)
Dosing: Once-daily subcutaneous injection adjusted by weight and tolerability.
Clinical Efficacy: Leads to an average of >10% weight loss at 1 year and a profound reduction in hyperphagia scores.

Medication Class	Key Adverse Effects	Essential Monitoring Parameters
GLP-1 RAs & Dual Agonists (Semaglutide, Liraglutide, Tirzepatide)	Nausea, vomiting, diarrhea, constipation, risk of cholelithiasis, theoretical risk of medullary thyroid carcinoma.	Baseline and periodic renal function; monitoring for persistent abdominal pain (pancreatitis) and gallbladder disease.
Phentermine/Topiramate ER	Paresthesias, insomnia, cognitive dysfunction, tachycardia, teratogenicity (cleft lip/palate).	Monthly pregnancy tests for post-menarcheal girls (REMS program); baseline and periodic serum bicarbonate and electrolytes; heart rate.
MC4R Agonists (Setmelanotide)	Skin hyperpigmentation, injection site reactions, sexual dysfunction (spontaneous erections), depression/suicidal ideation.	Regular skin examinations; baseline and ongoing psychiatric/mood assessment.

Chronicity of Therapy: Clinical trials show significant weight regain upon discontinuation of GLP-1 receptor agonists and setmelanotide, indicating that long-term, potentially lifelong therapy is required to maintain weight reduction.
Cost and Accessibility: High financial barriers and lack of structured transition pathways from pediatric to adult specialized obesity services remain major challenges.